Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
J.S. Malter, B.C. Ray, P.R. Westmark and C.J. Westmark
Affiliation: R509T, Waisman Center, 1500 Highland Ave, Madison, WI 53705, USA.
As the mechanisms underlying neuronal development and degeneration become clarified, a number of common effectors and signaling pathways are becoming apparent. Here we describe the identification of Aβ, long considered a pathologic mediator of Alzheimers Disease and Down Syndrome, as similarly over-expressed in the neurodevelopmental disease, Fragile X Syndrome. We also show that mGluR5 inhibitors, currently employed for the treatment of Fragile X, reduce Aβ production in rodent models of Fragile X and AD as well as reduce disease phenotypes including seizures. Thus seemingly disparate neurologic diseases may share a common pathologic instigator and be treatable with a common, currently available class of therapeutics.
Keywords: Metabotropic glutamate receptors (mGluR), Fragile X Syndrome (FXS), amyloid precursor protein (APP), beta-amyloid
Rights & PermissionsPrintExport